ANTABIO has developed a rich portfolio of first-in-class programs targeting high unmet needs in the antibacterial space. In 2013 ANTABIO received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to fund the development of a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases up to preclinical candidate nomination. In 2015, ANTABIO received a second Wellcome Trust Seeding Drug Discovery Award (€4.0 Million) to support the development of novel small molecule drugs for the treatment of chronic Pseudomonas infections in Cystic Fibrosis (CF) patients. In addition, ANTABIO has established an industrial discovery engine supported by Bpifrance (the French public investment bank) which is dedicated to the discovery, evaluation and development of new combination and/or adjunctive antibiotic therapies.

MBLi: Metallo Beta-Lactamases inhibitors

PEi : Pseudomonas Elastase inhibitors (powered by CARB-X)